Clinically reviewed · October 9, 2026. Priority labels reflect Atlas’s editorial judgment, not formal evidence grades.
5 briefs
DyslipidemiaPractice Changing
A new starting point for the lipid conversation.
Clinically reviewed Oct 9, 2026
What changed
The 2026 multisociety dyslipidemia guideline adopts PREVENT-ASCVD for risk-based primary prevention and brings back risk-specific LDL goals.
Why it matters
The risk framework has changed; an older calculator’s percentage is not interchangeable with the new categories.
What to do
Review your risk-calculation workflow and consult the guideline’s patient-specific pathway before changing treatment.
Keep the nuance. Risk-based primary prevention is not the pathway for every patient. Established ASCVD and severe hypercholesterolemia require separate consideration.
The 2026 guideline recommends measuring Lp(a) at least once in adulthood.
Why it matters
Lp(a) adds inherited-risk information that a routine lipid panel does not provide.
What to do
Check for a prior result before ordering, then interpret it alongside the patient’s overall risk.
Keep the nuance. Lp(a) is largely genetically determined. Routine repeat testing is generally unnecessary; lifestyle changes have little effect on its level.
The 2025 multisociety hypertension guideline recommends a urine albumin-to-creatinine ratio for all patients with high blood pressure; the 2017 guideline treated it as optional.
Why it matters
An initial workup that omits albuminuria testing may miss information about kidney health.
What to do
Review your hypertension order set and check whether urine albumin-to-creatinine ratio is included.
Keep the nuance. This is a focused implementation note about the 2025 guideline, not breaking news or a complete hypertension pathway. Interpret abnormal results in clinical context.
Multi-cancer blood tests: a signal worth following.
Clinically reviewed Oct 9, 2026
What changed
The NHS-Galleri trial’s first results did not meet its primary endpoint: reducing stage 3 and 4 cancers combined. Fewer stage 4 cancers were found in the tested group, offering a signal for further follow-up.
Why it matters
An encouraging secondary finding does not establish that screening saves lives. The trial team plans further follow-up for cancer mortality.
What to do
Atlas interpretation: follow the longer-term outcomes before treating this result as a reason to change routine screening. Continue established screening and discuss the limits of any additional test.
Keep the nuance. This brief addresses the May 2026 trial results, not a regulatory-status update. Watch means unresolved evidence worth tracking; it does not mean dismissing a positive result or a patient’s symptoms.
Glucose readings from a ring? Set the claim aside.
Clinically reviewed Oct 9, 2026
What changed
In its 2024 safety communication, the FDA warned against watches and rings claiming to measure glucose on their own without piercing the skin. This is an older safety reminder, not a new alert.
Why it matters
Unsupported readings can lead to unsafe medication decisions. A marketing claim is not evidence that a device can guide diabetes care.
What to do
Do not use these readings to adjust medication. Help patients choose an appropriate FDA-authorized glucose-monitoring device and address any concerns about readings or symptoms.
Keep the nuance. Ignore the unsupported claim, not the patient. This does not refer to a smartwatch displaying readings from an authorized continuous glucose monitor; that is a different function.
We separate a source’s findings from Atlas’s interpretation. Guidelines, original research, and official safety communications take priority over headlines.
AI may assist with first drafts and source checks. Clinical approval requires review by a clinician; source checking alone does not mean a brief has been clinically approved.
Every brief shows the source date, source-check date, and clinical-review status. Older guidance is labeled by its actual date, not presented as today’s news. Material corrections will be dated on the affected brief.
A recommendation or finding that may change a clinical workflow or decision.
Useful
Practical context or a focused improvement worth bringing into care.
Watch
Promising or unresolved evidence that needs more follow-up before routine adoption.
Ignore for Now
A claim without enough support to change routine practice—not a reason to ignore an individual patient.
A little clarity in your inbox
The next useful thing. When it’s ready.
New clinical tools, short teaching, and updates worth your time.
Subscribe to receive Atlas Health education and resource updates. Unsubscribe anytime. Privacy details
Have a clinical question? Suggest a topic →
What should Atlas cover next?
Please don’t include patient details or personal medical information. Suggestions help shape future content; individual responses aren’t guaranteed. This form is not for medical advice.